Drug reference
ipilimumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Monoclonal antibody(Oncology))
Mechanism of action
Recombinant, human cytotoxic T-lymphocyte antigen 4 (CTLA-4) - blocking antibody CTLA-4 is a negative regulator of T-cell activation; ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86 Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation.
Common side effects
- Pruritus
- Rash
- Fatigue
- Colitis
- Dermatitis immune-mediated manifestations
- Diarrhea
Related conditions
Frequently asked questions
What drug class is ipilimumab?
ipilimumab belongs to: Oncology.
How does ipilimumab work?
Recombinant, human cytotoxic T-lymphocyte antigen 4 (CTLA-4) - blocking antibody CTLA-4 is a negative regulator of T-cell activation; ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86 Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation.
What are the common side effects of ipilimumab?
Pruritus, Rash, Fatigue, Colitis, Dermatitis immune-mediated manifestations, Diarrhea
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.